iRhythm Holdings, Inc. (IRTC)
NASDAQ: IRTC · Real-Time Price · USD
126.44
+3.28 (2.66%)
At close: Aug 14, 2026, 4:00 PM EDT
126.11
-0.33 (-0.26%)
Pre-market: Aug 17, 2026, 6:47 AM EDT
iRhythm Holdings Employees
iRhythm Holdings had 2,400 employees as of December 31, 2025. The number of employees increased by 400 or 20.00% compared to the previous year.
Employees
2,400
Change (1Y)
400
Growth (1Y)
20.00%
Revenue / Employee
$343,890
Profits / Employee
-$5,811
Market Cap
4.17B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,400 | 400 | 20.00% |
| Dec 31, 2024 | 2,000 | 0 | - |
| Dec 31, 2023 | 2,000 | 207 | 11.54% |
| Dec 31, 2022 | 1,793 | 93 | 5.47% |
| Dec 31, 2021 | 1,700 | 543 | 46.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bruker | 11,085 |
| Integer Holdings | 11,000 |
| UFP Technologies | 4,846 |
| LivaNova | 3,300 |
| Haemonetics | 3,009 |
| Neogen | 2,636 |
| Establishment Labs Holdings | 1,004 |
| TransMedics Group | 898 |
IRTC News
- 4 hours ago - Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 6 days ago - iRhythm price target raised to $168 from $160 at Truist - TheFly
- 9 days ago - iRhythm price target lowered to $192 from $255 at Needham - TheFly
- 10 days ago - iRhythm price target raised to $165 from $150 at Evercore ISI - TheFly
- 10 days ago - iRhythm price target raised to $165 from $160 at Baird - TheFly
- 10 days ago - iRhythm price target raised to $196 from $157 at Canaccord - TheFly
- 10 days ago - iRhythm to acquire VitalConnect for total consideration of $287.5M - TheFly
- 10 days ago - iRhythm Holdings Earnings Call Transcript: Q2 2026 - Transcripts